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Orthotopic liver transplantation is the accepted treatment for endstage liver disease. In the US alone, more than 
3 000 patients receive liver transplants yearly distributed through more than 100 liver transplant programmes. 
Neurological complications occur in up to 47% of these patients. Among them, seizures are one of the most 
common. They tend to occur during the first few weeks after transplantation. Generalized seizures are the most 
frequently encountered. Their aetiology is usually multifactorial requiring a comprehensive diagnostic and 
therapeutic approach. Seizures must be differentiated from a variety of behavioural and movement disorders. In 
this review article, the frequency and time of occurrence of seizures, their types and aetiology, diagnostic 
approaches and treatment are discussed. 
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INTRODUCTION 
Orthotopic liver transplantation (OLT) has be- 
come the standard surgical procedure and fully 
accepted treatment for patients with endstage 
liver disease and fulminant hepatic failure. 
According to United Network for Organ Sharing 
(UNOS) data, in the US, 3 443 patients received 
liver transplants in 1993’. At the University of 
Nebraska Medical Center (UNMC), by April of 
1996, 1167 liver transplant procedures had been 
performed since the initiation of our liver 
transplantation program in 1985. The vast major- 
ity of the patients are doing well after the 
transplant with a 5-year survival rate of 75%; 
however, a group of patients experience neurolo- 
gic complications. Among them, seizures are the 
most frequent. In the post-transplant setting, 
neurologists are consulted most commonly for 
evaluation of mental ‘status changes and for 
diagnosis and treatment of seizures. In this review 
article, frequency and time of occurrence of 
seizures in OLT patients, types of seizures, their 
aetiology, diagnostic assessment and treatment 
are discussed. 
FREQUENCY AND TIME OF OCCURRENCE 
Seizures are a common occurrence in the OLT 
population. In clinical consecutive series, the 
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frequency of seizures varies between 2.8 and 42% 
and in autopsy series the frequency varies 
between 8.1 and 35% (Table 1)2-“. Seizures tend 
to occur in a bimodal distribution within the first 7 
days after transplantation and between 5 and 16 
weeks after transplantation (Fig. 1)12. Patients 
who are undergoing retransplantation are also at 
high risk of developing seizures. In a series of 185 
patients who had two or more OLTs, seizures 
occurred in 33%‘3. 
TYPES OF SEIZURES 
Generalized seizures are the most common type 
of seizure observed after OLT. Clinically, how- 
ever, it is often difficult to determine if a given 
seizure was generalized from its onset or whether 
it was secondarily generalized, as the focal onset 
may have been brief and lacked clinical detection. 
For this reason, there is a tendency to under- 
estimate the prevalence of seizures of focal origin 
and this also applies to the transplant population. 
Summarizing a number of clinical and autopsy 
series; generalized seizures were seen in 39 
patients, focal seizures in 10 patients, status 
epilepticus in five patients, and myoclonic 
seizures in three patients (Table 1)““. Sex dis- 
tribution was discussed in only three articles: 
(M:F = 3:1)“, (4:0)“, and (3:4)6. 
0 1997 British Epilepsy Association 
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Table 1: Seizures after OLT: consecutive series 
Series Year Study Total number of Age range Types of Presumed etiology of seizure 
published type patients (mean) yearsh seizures (number of patients) 
(number with (number of 
seizures)’ patients) 
Starzl el al’ 
Adams er al3 
Busuttil er al’ 
Martinez er al5 
Hall and 
Martinez” 
Krom er al’ 
Power et al’ 
Ferreiro et al” 
Stein el at” 
Moreno er al” 
1978 C/A 
1987 C 
1987 C 
1988 A 
1989 A 
1989 C 
1990 A 
1992 A 
1992 C 
1993 C 
48(6) 
52( 13) 
83(18) 
85(30) 
35(10) 
83(7) 
27(8) 
37(3) 
40(8) 
143(4) 
na 
5-59 
(29) 
na 
9 months- 
18 years 
(6 years) 
na 
na 
na 
28-52 
(40) 
23-56 
(45) 
GTC(na) 
Wa) 
GTC(10) 
F(1) 
SE (2) 
M 69 
GTC (18) 
GTC(ll) 
F (6) 
SE (2) 
M (1) 
na(l5) 
na 
na 
GTC (6) 
F(2) 
F(n4 
SE(na) 
Wna) 
GTC (8) 
F(1) 
GTC (4) 
SE(l) 
na 
Electrolyte disturbance (10) 
na (3) 
Sepsis leading to brain herniation 
and death (1) 
Multifactorial (17) 
Hypomagnesemia (15) 
Electrolyte disturbance (2) 
Cryptococcal leptomeningitis (1) 
Major neurologic event 
(subarachnoid hemorrhage. 
intracerebral hemorrhage, brain 
herniation) (8) 
Cardiac arrest (2) 
Subtherapeutic antiepileptic drug 
levels in a patient with prior 
epilepsy (1) 
na 
Cyclosporine (6) 
Listeria meningitis (1) 
Hypomagnesemia (8) 
Cyclosporine (na) 
Cerebral structural abnormalities 
[hemorrhage, infarction, 
infection] (na) 
Structural lesions (na) 
Metabolic derangements (including 
anoxic-ischemic encephalo- 
pathy) @a) 
Cyclosporine (na) 
na 
Multifactorial (metabolic 
derangements; decrease in 
cholesterol, calcium, and 
magnesium levels: cyclosporine; 
graft dysfunction: previous 
neurologic condition) (na) 
Cylosporine 
leukoencephalopathy (1) 
C, clinical series containing non-autopsied or living patients only; A, autopsy series; C/A, mixed series containing non-autopsied or 
living patients and autopsied patients; na, information not available; OLT, orthotopic liver transplant: “total number of patients 
included in the series versus the number of patients (in patenthesis) with seizures; ‘age range of those patients with seizures: GTC, 
generalized tonic-clonic seizure; F, focal seizure; SE, status epilepticus; M, myoclonic seizure. 
One of the most common indications for 
performing an EEG after OLT is for the 
evaluation of mental status changes. Not infre- 
quently, non-convulsive seizures are detected. 
Status epilepticus was encountered in many 
patients in clinical series (Table 1). Focal seizures 
also occur and should alert the clinician to seek a 
structural lesion. As generalized seizures may be 
of focal onset, they should also prompt clinical 
investigation for a focal lesion. Occasionally the 
neurologist is consulted because the post-OLT 
patient develops myoclonus, tremor or other 
abnormal movements which may or may not be 
epileptic in nature. It is well known that 
cyclosporine can provoke both seizures and 
movement disorders, such as tremors or 
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Fig. 1. Time of occurrence of initial seizure following liver 
transplantation. (Constructed from data in Table 1) 
myoclonus’4~‘5. Multichannel surface EMG 
studies combined with EEG may delineate the 
cause in such cases. We have observed two 
patients with cyclosporine toxicity who were 
obtunded and exhibited coarse tremors in the 
upper extremities. Their combined EEG and 
EMG tracings confirmed a non-epileptic nature 
of their movement disorder. 
AETIOLOGY 
The aetiology of seizures after OLT is usually 
multifactorial. However, in many cases a single 
aetiology may be present. While seizures in 
the OLT recipient may often occur due to focal 
brain injury, metabolic abnormalities may 
predispose these patients to seizures as suggested 
in earlier reports12. The most commonly iden- 
tified underlying causes for seizures in OLT 
recipients include metabolic derangements, drugs 
(especially cyclosporine and OKT3), hypoxic- 
ischemic injury, cerebral structural lesions, and 
infection3-5’7-9.ll.12.‘“. 
Electrolyte disturbances 
A variety of electrolyte disturbances have been 
encountered in liver transplant patients. How- 
ever, those most frequently responsible for sei- 
zures include hypomagnesemia, hypocalcemia, 
and hyponatremia3-5*8*9V”V12*16*17. Seizures oc- 
curred in 20% of U.C.L.A. patients following 
liver transplantation, usually in the setting of 
hypomagnesemia and high cyclosporin A levels. 
Cyclosporin A is known to cause magnesium 
wasting, and magnesium levels must be 
monitored17. An electrolyte abnormality may 
occur alone, in combination with other metabolic 
derangements, or accompany other potential 
aetiologies for seizures. 
Medication effects 
After OLT, patients are treated with im- 
munosuppressant medications. Those which have 
been identified as possible causes of seizures 
include cyclosporine, OKT3 and FK 506. Nephro- 
toxicity, neurotoxicity, and impaired glucose 
metabolism are commonly associated with the use 
of either FK 506 (tacrolimus) or. cyclosporine. 
The incidence of adverse neurologic events 
including tremor and paraesthesia have been 
reported to be significantly higher with FK 506 
compared to cysclosporine, while severe adverse 
neurologic events such as convulsions are rela- 
tively rare with the use of either of these two 
agents . 18V19 In this clinical setting, dose reduction 
or discontinuation of the offending medication 
usually leads to complete recovery20*2’. There are 
a number of experimental immunosuppressive 
agents under study in liver transplantation in- 
cluding rapamycin, RS61443 (mycophenolic acid 
mofetyl), deoxyspergualin, brequinar, prostag- 
landins, thalidomide, ursodeoxycholic acid, mon- 
oclonal antibodies, antithymocyte globulin, 
anti-CD45 monoclonal antibody, antibodies to 
lymphocyte antigens, anticytokine antibodies and 
antiadhesion molecules . I4 Presently, their relative 
potential to induce seizures is not known. High 
dose steroids for treatment of graft rejection have 
also been implicated in seizures. 
Following OLT, patients may develop pulmo- 
nary complications requiring treatment with 
theophylline. Theophylline related seizures 
usually occur with elevated or toxic blood levels; 
however, it may contribute to seizures in patients 
with other potential causes such as electrolyte 
disturbances or infection. As patients with liver 
disease exhibit decreased demethylation of 
theophylline, seizures may occur with therapeutic 
levels of this drug, especially if the patient is also 
receiving quinolone derivatives, such as cipro- 
floxacin and norfloxacin22-24. In patients with 
infection requiring antibiotics, caution should be 
exercised especially with mezlocillin and im- 
ipenem which are also known to precipitate 
seizures22. 
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Cerebral structural lesions 
A variety of cerebral structural lesions which 
have been reported to occur more commonly in 
OLT patients include intracerebral haemorrhage, 
subarachnoid haemorrhage, cerebral infarction, 
and brain abscess, all of which may contribute to 
seizures5s8,9. In the UNMC-Mayo Clinic joint 
study of patients with neurologic abnormalities 
after OLTz5, there were 11 patients who had 
seizures and also underwent autopsy. Eight of 
them had a structural abnormality. In another 
autopsy series by Martinez et a15, 30 patients had 
seizures following OLT. Eight were found to 
have subarachnoid haemorrhage, intracerebral 
haemorrhage, or brain haerniation. Overwhelm- 
ing infection in the liver transplant recipient may 
predispose intracerebral haemorrhagez6. 
Infection 
The most common are fungal and viral infections 
of the central nervous system (CNS). Aspergil- 
losis is the most common fungal infection of the 
CNS in the OLT recipient. Cryptococcal 
leptomeningitis5, listeria meningitis’, and a myco- 
bacteria tuberculosis abscess2’ have also been 
reported to cause seizures in OLT recipients. 
Ebstein-Barr virus infection can cause a post- 
transplant lymphoproliferative disease. The clini- 
cal presentation includes unexplained fever, 
malaise, lymphadenopathy, gastrointestinal ab- 
normalities including gut perforation, and central 
nervous system dysfunction including mental 
status changes, focal neurologic signs, and 
seizures2829. 
Less common causes 
Hypoxic-ischemic encephalopathy may result 
from abnormalities in blood pressure control, 
respiratory arrest and graft rejection and give rise 
to seizures. Pre-existing neurologic conditions 
including prior epilepsy and the inadvertent 
discontinuation of antiepileptic medication or 
subtherapeutic antiepileptic blood levels are also 
potential causes for seizures after OLT. The 
effect of OLT on seizure control in patients with a 
prior history of epilepsy is presently not known. 
OLT has become a more widely utilized proce- 
dure in patients with Laermec’s cirrhosis. Recidi- 
vism rates up to 50% have been reported 
following transplantation3’ and these patients are 
at risk for alcohol withdrawal and alcohol-related 
seizures. 
DIAGNOSTIC ASSESSMENT 
A variety of diagnostic tests must be implemented 
due to the many potential causes of seizures 
following OLT. The most frequently utilized are 
EEG “Zig’ (Figs 2-5) and CT of the head. 
According to Moreno et al, CT was used 85.7% 
and EEG 42.8% of the time in the evaluation of 
OLT patients with neurologic complications”. 
The utilization of specific tests will of course 
depend on the patient’s individual clinical under- 
lying condition. The CT scan has the advantage of 
being readily available and can provide useful 
clinical information such as the presence of 
intracranial haemorrhage; however, MRI has 
superior brain tissue resolution making it a more 
sensitive study. However, MRI is more difficult to 
obtain in the critically ill patient, particularly in 
the intubated patient and patients who are unable 
to remain still. Therefore, a CT scan of the head 
remains the first diagnostic option. 
In patients with altered mental states, the EEG 
can help differentiate an encephalopathic state 
from non-convulsive status epilepticus, and tre- 
mors from true seizure activity (Fig. 5). EEG is 
also helpful in prognosis. In our series2’, epilep- 
tiform activity on the EEGs of patients who had 
undergone OLT was associated with a variety of 
structural abnormalities, including intracranial 
haemorrhage, cerebral oedema, pontine and 
extrapontine myelinolysis, and cortical infarctions 
leading to a complicated clinical course and a 
shortened survival. 
The other diagnostic tests utilized in the 
evaluation of the OLT patient with seizures are 
presented in Table 2. In those patients with 
pre-existing seizure disorders, it is especially 
important to measure blood levels of adminis- 
tered anticonvulsants. 
MANAGEMENT 
Treatment of the OLT patient who has seizures is 
challenging since there are numerous aetiologies 
in this patient population. Treatment of the 
underlying cause of the seizures should always be 
undertaken together with the administration of 
anticonvulsant medication. Special attention 
should be given to the correction of electrolyte 
imbalances, treatment of infection, and intra- 
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Fig. 2. EEG of 28-month-old female who underwent four OLTs. The first OLT was performed with a living related donor at the 
age of 8 months for biliary atresia. The subsequent OLTs were cadaveric and were performed for chronic biliary obstruction and 
liver rejection. The entire hospital course was complicated by several small intestinal perforations leading to peritonitis. After 
the fourth OLT performed 15 days prior to death, the patient experienced mental status changes. An EEG obtained 12 days prior 
to death (a-c) demonstrated generalized delta slowing and several focal electrographic seizure discharges emanating from 
the right occipital head region: (a) the beginning of the seizure discharge showing repetitive low-amplitude sharp waves over 
the right occipital area; (b) 2.5 minutes later, high-voltage spike, polyspike-slow wave complexes maximal over the right 
occipital area with limited spread to the left occipital area; (c) 2 minutes later, the seizure discharge abruptly terminates. (d) An 
EEG performed the following day showed an electrographic seizure discharge emanating from the left occipital area with some 
spread to the right occipital region, superimposed upon a markedly slow background. On clinical examination, the patient was 
comatose with a right-hemiparesis. There were no clinical seizures observed throughout the hospitalization. CT of the head 
showed generalized cerebral oedema. The patient died due to multiple medical complications. Autopsy revealed hepatic 
artery thrombosis, intestinal perforation, diffuse peritonitis, and pulmonary haemorrhages. The intracranial contents were not 
examined. 
cranial haemorrhage. Neurosurgical management 
may be necessary in selected cases such as 
cerebral abscess or subdural haematoma. 
In our experience, the most useful anticonvul- 
sant in patients who have undergone OLT is 
phenytoin. Although the recommended loading 
dose is lo-20 mg/kg body weight, we find doses 
in the 18-20 mg/kg range necessary to achieve 
high therapeutic levels. Both total and free 
phenytoin levels should be measured, because 
patients who have undergone OLT may have 
hypoalbuminemia and decreased protein binding 
of phenytoin. This can result in a toxic free 
phenytoin level when the total level is in the usual 
therapeutic range and a therapeutic free 
phenytoin level may be achieved when the total 
level is in the subtherapeutic range. This is 
especially likely to occur if the blood urea 
nitrogen (BUN) and creatinine levels are 
increased33. 
Phenobarbital is also a frequently used anti- 
convulsant medication; however, because pheno- 
barbital can cause excessive sedation, hypo- 
tension during intravenous administration and 
respiratory suppression, phenytoin remains the 
drug of choice. The intravenous loading dose of 
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Fig. 3. EEG of 56-year-old male who underwent two 
cadeveric OLTs. The first OLT was performed for endstage 
liver disease due to primary biliary cirrhosis and the second 
for acute rejection. Nine days after the second OLT the 
patient was comatose and exhibited generalized tonic- 
clonic seizures. His hospital course was complicated by 
acute necrotizing bronchopneumonia and renal failure. Two 
days later he died and post-mortem examination revealed 
severe cerebral oedema with herniation and scattered 
neuronal necrosis. Generalized periodic spike, polyspike 
discharges are superimposed upon a slow background and 
are associated with generalized clonic activity. 
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phenobarbital is not well established, but is 
generally in the range of 8-20 mg/kg. Respiratory 
suppression may accompany the administration 
of such doses, especially when other 
anticonvulsant drugs with respiratory suppressant 
effects, particularly diazepam and lorazepam, 
have been administered before phenobarbital. 
Carbamazepine can be utilized, but due to the 
lack of an intravenous preparation and the 
difficulty in administering loading doses, it is 
rarely used unless the patient has a history of 
epilepsy and was on carbamazepine preopera- 
tively. For the same reason, valproic acid is not 
frequently used and in addition, it possesses 
greater hepatotoxicity. 
It should be noted that carbamazepine, pheno- 
barbital, phenytoin and primidone may decrease 
cyclosporine blood levels by induction of P- 
450111A (cyclosporine oxidase)22-2J. This process 
may take up to 10 days to occur. Ergotamine 
(b) 
FPI-AI F 
FP2-A2 Mw 
F3-A’ +-f++@-- 
F4-A2 - 
C3-AI 
C4-A2 \ 
P3-AI 1 
P4-A2 \ 
OI-AI + 
02-A2 v 
b 5op 
FPl-AI 
FP2-A2 
tTAl L 
F4-A2 
C4-A2 \ 
P3-A1 & 
P4-A2 Q 
Ol-A1 
02-A2 > 
2 sopv 
Fig. 4. EEG of a 57-year-old man who underwent cadaveric OLT for endstage liver disease due to chronic alcoholism. The 
post-operative course was complicated by a respiratory arrest during which hypotension occurred on the 40th post-operative 
day. Following the arrest, he developed recurrent myoclonic and generalized tonic-clonic seizures. (a) An EEG performed on 
the day following the respiratory arrest revealed high-voltage generalized periodic spike, polyspike-and-wave complexes on a 
suppressed background. (b) Later in the EEG recording the patient exhibited bilateral facial jerking, reflected on the EEG as 
repeated myogenic potentials, most likely intermixed with polyspike-and-wave discharges superimposed upon a suppressed 
background. (c) Two minutes following the intravenous administration of 2 mg of lorazepam, the facial twitching abruptly 
subsided and the EEG demonstrates a diffusely suppressed low-voltage background in the theta and delta frequency range, 
with superimposed beta activity, probably due to a medication effect. EEG tracing reprinted with permissio?‘. 
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Fig. 5. EEG of a 61-year-old male liver transplant recipient who sustained a cardiopulmonary arrest on the previous day. At the 
time of the EEG recording, the patient was exhibiting intermittant jaw tremors: (a) during periods of jaw tremors, the EEG tracing 
is contaminated by myogenic potentials; (b) following neuromuscular blockage with 2 mg of pancuronium, a burst-suppression 
pattern is evident. The jaw tremors were not believed to be of epileptic origin. 
derivatives which are used to treat vascular 
headaches may lead to increased cyclosporine 
blood levels through the inhibition of cyclo- 
sporine oxidase**. 
Felbamate, gabapentin and lomotrigine are 
newly released anticonvulsants, the latter two for 
add-on therapy. There are no published reports 
on the use of these medications in the liver 
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Table 2: Diagnostic tests useful in the evaluation of seizures 
after orthotopic liver transplantation. 
Electroencephalography 
Routine awake and sleep recordings 
Prolonged recording for observalion of response to 
antiepileptic medication 
Imaging studies 
Computed tomographic scan with and without iodinated 
contrast 
Magnetic resonance imaging (MRI) with and without 
gadolinium 
MRI with angiographic sequences 
Laboratory tests 
Blood testing 
Complete blood count 
Coagulation measurements 
Ammonia 
Liver enzymes 
Electrolytes including calcium and magnesium 
Osmolality 
Cultures for bacteria, viruses, and fungi 
Serologic tests 
Arterial blood gases 
Blood levels of administered drugs (cyclosporine, 
theophylline. and anticonvulsants) 
Cerebrospinal fluid studies 
Gram stain 
Cell count with differential 
Protein and glucose content 
Cultures for bacteria, viruses, and fungi 
VDRL 
Modified and reprinted with permission3’. 
transplant patient. However, gabapentin is a 
potentially attractive agent in liver transplanta- 
tion because it is not appreciably metabolized by 
the liver, but rather is eliminated by renal 
excretion. 
Treatment of status epilepticus requires the 
administration of intravenous anticonvulsants 
such as phenytoin and phenobarbital together 
with a benzodiazepine. Several intravenous ben- 
zodiazepine preparations are available including 
diazepam, lorazepam and midazolam. All are 
very effective anticonvulsants. However, we 
prefer to use lorazepam due to its longer 
antiepileptic duration of action. For status epilep- 
ticus refractory to benzodiazepines, phenytoin 
and phenobarbital, the administration of anaes- 
thetic doses of pentobarbital with EEG monitor- 
ing may be necessary. 
SUMMARY 
In summary, despite continued progress in liver 
transplantation, seizures continue to be a sig- 
nificant neurologic complication. Generalized 
seizures are probably the most common. There 
are a variety of causes including metabolic 
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abnormalities, infection, and intracranial haem- 
orrhage, occurring alone or in combination. In 
our transplantation program, we have observed a 
trend for seizures to occur less frequently than at 
the start of the program as was also observed by 
Dr Stein and his colleagues”. 
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